Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Acute Ischemic Stroke
NCT02730455Phase 2Completed
- Sponsor
- Biogen
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of natalizumab in ischemic stroke (3 arms), sponsored by Biogen. Primary endpoint: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90. Started Jul 2016; status: completed.
02
Drugs
natalizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02730455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730455.